You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 146 No. 5, May 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of Somatotropin of Mammalian Cell Origin in Growth Hormone Deficiency

S. Douglas Frasier, MD; Craig R. Rudlin, MD; Hans J. Zeisel, MD; Hannen H. Liu, MD, PhD; Pamela C. Long; Boris Senior, MD; David N. Finegold, MD; Barry B. Bercu, MD; James F. Marks, MD; Geoffrey P. Redmond, MD

Am J Dis Child. 1992;146(5):582-587.


Abstract

• Sixty-nine growth hormone—deficient patients were treated for 1 year with somatotropin (recombinant DNA-derived human growth hormone) produced in mouse cells. The growth velocity of the 50 patients (72%) in whom the effectiveness of this growth hormone could be evaluated increased from a mean (±SD) 3.5±1.1 to 8.7±1.6. cm/y. An enhanced rate of weight gain was also observed. Bone age was not unduly accelerated. One of 66 patients developed antibodies to recombinant growth hormone, which did not affect the response to therapy. No patient developed antibodies to host cell proteins. An increased insulin response to a standard glucose load, without any change in glucose tolerance, was observed after 1 year of treatment. This authentic sequence human growth hormone preparation produced in mammalian cells is both effective and safe in the treatment of children with growth hormone deficiency.

(AJDC. 1992;146:582-587)



Author Affiliations

From the Departments of Pediatrics, UCLA and the Olive View Medical Center, Sylmar, Calif (Dr Frasier); The University Children's Hospital, Freiburg, Germany (Dr Zeisel); Serono Laboratories Inc, Norwell, Mass (Dr Liu and Ms Long); New England Medical Center Hospitals, Boston, Mass (Dr Senior); Children's Hospital of Pittsburgh, Pa (Dr Finegold); University of South Florida, All Children's Hospital, St Petersburg (Dr Bercu); The University of Texas Southwestern Medical Center, Dallas (Dr Marks); and Cleveland (Ohio) Clinic (Dr Redmond).


Footnotes

Accepted for publication November 19, 1991.

Reprint requests to Department of Pediatrics, Room 3A108, Olive View Medical Center, 14445 Olive View Dr, Sylmar, CA 91342-1495 (Dr Frasier).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.